Odronextamab: Promising Results in Treating Relapsed/Refractory Follicular Lymphoma: Findings from Phase II Study ELM-2 Tae Min Kim MD - Synopsis below extracted from the video transcript.
The Odronextamab trial is using a CD20xCD3 bispecific antibody and a monoclonal antibody targeting follicular lymphoma cells in the second line failure setting. The trial has shown high complete response rates with deep and doable responses in patients with relapsed and refractory follicular lymphoma. The standard of care for relapsed and refractory follicular lymphoma has limited treatment options, and patients often require multiple rounds of treatment. Odronextamab is a novel bispecific antibody that targets CD20 and CD3 proteins found on the surface of cancerous B-cells and T-cells, respectively. The drug brings these cells in close proximity, resulting in the destruction of the cancer cells.
Read The Full Transcript and Watch The Video Here
In the ELM-2 research, individuals with relapsed or refractory follicular lymphoma who had previously been treated with at least two different types of chemotherapy were examined to see whether or not odronextamab was both safe and effective. According to the findings of the study, the total response rate was 70.4%, and the percentage of full responses was 42.2%. It was amazing how long people took to respond, with the median time being 21.7 months. According to the findings of the study, odronextamab exhibited a controllable safety profile, and there were no newly discovered safety signals. The most prevalent adverse effects were linked to cytokine release syndrome (CRS) and neurotoxicity, both of which were generally mild or moderate in intensity and were controllable with supportive treatment. Based on these findings, odronextamab appears to have the potential to become an exciting new therapeutic option for individuals who have relapsed or refractory cases of follicular lymphoma. To verify both its usefulness and its safety, more research is required.
